In addition, further clinical intervention trials are also needed to clarify whether blockade of the crosstalk between the AGE-RAGE axis and thrombin-PAR-1 axis could actually decrease the risk of thromboembolic disorders and slow the progression of atherosclerosis in patients with AF, especially in diabetic subjects. Here, RENBP is linked to atherosclerosis.